Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASH 2024 Insights: Incorporating Nivolumab and Brentuximab Vedotin I…

2024 ASH Annual Meeting Insights Hub

A. LaCasce

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options in L…

2024 ASCO® Annual Meeting Insights Hub

P. Johnson

ASH 2024 Insights: Pembro Maintenance instead of ASCT for Pts With R…

Memorial Sloan Kettering Cancer Center

A. Moskowitz

Treatment Updates and Management of Hodgkin Lymphoma

Integrity CE

A. Niu, D. Wallace, M. Cortese

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Emerging and Current Treatment for Hodgkin Lymphoma in 2024

Indy Hematology Review

S. Ansell

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

Summary of Recent Updates in Advanced Hodgkin Lymphoma

SOHO Brazil 2024

C. Moskowitz

2024 Updates in the Management of DLBCL, FL, and HL

UNC Lineberger Comprehensive Cancer Center

A. Beaven

UChicago Medicine Best of ASCO® 2024: HL, DLBCL, MCL

UChicago Medicine Annual Practice Updates in Hematology and Oncology

A. Rojek

Key Lymphoma Updates From ASH

Memorial Sloan Kettering Cancer Center

P. Torka

Practice-Changing Abstracts in NHL and HL From ASH 2023

UChicago Medicine

S. Smith

EHA 2024 Insights: Treatment of Advanced Stage, High-Risk Hodgkin's …

Insights from 2024 EHA Annual Meeting

M. Salamoon

Summary of Recent Updates in R/R HL

SOHO Brazil 2024

C. Moskowitz

Early Stage HL: Can Radiation Therapy Be Eliminated?

SOHO Brazil 2024

C. Moskowitz